IPA logo

ImmunoPrecise Antibodies (IPA) EBITDA

Annual EBITDA

-$16.99 M
-$1.17 M-7.42%

April 30, 2024

Summary

Performance

1-Year Change

-7.42%

3-Year Change

-1467.1%

5-Year Change

-455.53%

15-Year Change

-314.6%

IPA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

55.67%
IPA annual EBITDA is higher than 55.67% of companies in Healthcare sector

High & Low

All-time High

$68.90 K
IPA annual EBITDA is currently <-9900.00% below its historical high of $68.90 thousand

3-Year Low

-$16.99 M
IPA annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Apr 30, 2024
IPA previous annual earnings announcement was published on Apr 30, 2024

Next Annual Earnings Report Date

N/A
IPA next annual earnings announcement has not yet been scheduled

OtherIPAprofitabilitymetrics:

Annual Revenue

$18.16 M
IPA annual revenue is $18.16 million

Annual Net Income

-$20.12 M
IPA annual net profit is -$20.12 million

Annual EBIT

-$21.24 M
IPA annual earnings before interest & taxes is -$21.24 million

Annual EPS

-$0.78
IPA annual earnings per share is -$0.78

Quarterly EBITDA

-$1.12 M
+$1.35 M+54.74%

October 31, 2024

Summary

Performance

3-Month Change

+54.74%

1-Year Change

+54.74%

3-Year Change

+54.74%

5-Year Change

+54.74%

IPA Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.47%
IPA quarterly EBITDA is higher than 68.47% of companies in Healthcare sector

High & Low

All-time High

$611.70 K
IPA quarterly EBITDA is currently -282.46% below its historical high of $611.70 thousand

3-Year Low

-$12.70 M

Earnings dates

Last Quarterly Earnings Report Date

Oct 31, 2024
IPA previous earnings announcement was published on Oct 31, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
IPA next earnings announcement is scheduled for Mar 14, 2025

OtherIPAprofitabilitymetrics:

Quarterly Revenue

$4.49 M
IPA quarterly revenue is $4.49 million

Quarterly Net Income

-$1.87 M
IPA quarterly net profit is -$1.87 million

Quarterly EBIT

-$2.15 M
IPA quarterly earnings before interest & taxes is -$2.15 million

Quarterly EPS

-$0.07
IPA quarterly earnings per share is -$0.07

TTM EBITDA

-$17.87 M
-$208.40 K-1.18%

October 31, 2024

Summary

Performance

3-Month Change

-1.18%

1-Year Change

-1.18%

3-Year Change

-1.18%

5-Year Change

-1.18%

IPA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

52.37%
IPA TTM EBITDA is higher than 52.37% of companies in Healthcare sector

High & Low

All-time High

$1.70 M
IPA TTM EBITDA is currently -1151.75% below its historical high of $1.70 million

3-Year Low

-$17.87 M
IPA TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Oct 31, 2024
IPA previous earnings announcement was published on Oct 31, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
IPA next earnings announcement is scheduled for Mar 14, 2025

OtherIPAprofitabilitymetrics:

TTM Revenue

$17.69 M
IPA TTM revenue is $17.69 million

TTM Net Income

-$20.26 M
IPA TTM net profit is -$20.26 million

TTM EBIT

-$22.06 M
IPA TTM earnings before interest & taxes is -$22.06 million

TTM EPS

-$0.77
IPA TTM earnings per share is -$0.77

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$16.99 M
IPA annual EBITDA is -$16.99 million

Annual Net Income

-$20.12 M
IPA annual net profit is -$20.12 million

Annual Interest Expense

$14.10 K
IPA annual interest expense is $14.10 thousand

Annual Income Tax

-$1.13 M
IPA annual income tax is -$1.13 million

Annual D&A

$4.25 M
IPA annual depreciation & amortization is $4.25 million

IPA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-7.4%+54.7%-1.2%
3 y3 years-1467.1%+54.7%-1.2%
5 y5 years-455.5%+54.7%-1.2%

IPA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-1467.1%at low-23.0%+91.2%-153.1%at low
5 y5-year-4953.1%at low-282.5%+91.2%-1151.8%at low
alltimeall time<-9999.0%at low-282.5%+91.2%-1151.8%at low

ImmunoPrecise Antibodies EBITDA History

DateAnnualQuarterlyTTM
Oct 2024
-
-$1.12 M(-54.7%)
-$17.87 M(+1.2%)
Jul 2024
-
-$2.47 M(-80.6%)
-$17.66 M(+4.5%)
Apr 2024
-$16.99 M(+7.4%)
-$12.70 M(+700.5%)
-$16.90 M(+139.3%)
Jan 2024
-
-$1.59 M(+74.8%)
-$7.06 M(-7.5%)
Oct 2023
-
-$907.70 K(-46.6%)
-$7.63 M(-32.1%)
Jul 2023
-
-$1.70 M(-40.6%)
-$11.24 M(-29.4%)
Apr 2023
-$15.82 M(+65.5%)
-$2.87 M(+32.9%)
-$15.93 M(+1.0%)
Jan 2023
-
-$2.16 M(-52.3%)
-$15.76 M(+0.4%)
Oct 2022
-
-$4.52 M(-29.3%)
-$15.70 M(+10.2%)
Jul 2022
-
-$6.39 M(+136.6%)
-$14.25 M(+50.4%)
Apr 2022
-$9.56 M(+781.5%)
-$2.70 M(+29.2%)
-$9.47 M(+4.0%)
Jan 2022
-
-$2.09 M(-32.0%)
-$9.11 M(+28.3%)
Oct 2021
-
-$3.07 M(+90.4%)
-$7.10 M(+107.8%)
Jul 2021
-
-$1.61 M(-31.0%)
-$3.42 M(+177.9%)
Apr 2021
-$1.08 M(+222.5%)
-$2.34 M(+2906.6%)
-$1.23 M(-201.8%)
Jan 2021
-
-$77.70 K(-112.7%)
$1.21 M(-29.0%)
Oct 2020
-
$611.70 K(+6.7%)
$1.70 M(+86.1%)
Jul 2020
-
$573.10 K(+475.4%)
$912.90 K(-735.7%)
Apr 2020
-$336.30 K(-89.0%)
$99.60 K(-76.0%)
-$143.60 K(-92.4%)
Jan 2020
-
$414.60 K(-337.7%)
-$1.88 M(-31.8%)
Oct 2019
-
-$174.40 K(-63.9%)
-$2.75 M(-12.7%)
Jul 2019
-
-$483.40 K(-70.5%)
-$3.15 M(+3.6%)
Apr 2019
-$3.06 M(-10.2%)
-$1.64 M(+255.5%)
-$3.05 M(+13.6%)
Jan 2019
-
-$460.20 K(-20.0%)
-$2.68 M(-13.5%)
Oct 2018
-
-$575.30 K(+53.5%)
-$3.10 M(-2.0%)
Jul 2018
-
-$374.80 K(-70.5%)
-$3.16 M(-7.1%)
Apr 2018
-$3.41 M(-16.9%)
-$1.27 M(+44.6%)
-$3.41 M(+9.7%)
Jan 2018
-
-$878.80 K(+37.3%)
-$3.11 M(-44.0%)
Oct 2017
-
-$639.90 K(+3.5%)
-$5.54 M(+12.8%)
Jul 2017
-
-$618.40 K(-36.2%)
-$4.91 M(+14.2%)
Apr 2017
-$4.10 M(>+9900.0%)
-$969.60 K(-70.8%)
-$4.30 M(+29.1%)
Jan 2017
-
-$3.32 M(>+9900.0%)
-$3.33 M(+6565.2%)
Sep 2016
-
-$10.40 K(+48.6%)
-$50.00 K(+19.9%)
Jun 2016
-
-$7000.00(+133.3%)
-$41.70 K(+50.0%)
Mar 2016
-
-$3000.00(-89.9%)
-$27.80 K(+23.6%)
Dec 2015
-$24.20 K(-56.2%)
-
-
Dec 2015
-
-$29.60 K(+1309.5%)
-$22.50 K(+603.1%)
Sep 2015
-
-$2100.00(-130.4%)
-$3200.00(-88.5%)
Jun 2015
-
$6900.00(+200.0%)
-$27.80 K(-23.2%)
Mar 2015
-
$2300.00(-122.3%)
-$36.20 K(-34.5%)
Dec 2014
-$55.20 K(-180.1%)
-
-
Dec 2014
-
-$10.30 K(-61.4%)
-$55.30 K(-178.0%)
Sep 2014
-
-$26.70 K(+1680.0%)
$70.90 K(-8.2%)
Jun 2014
-
-$1500.00(-91.1%)
$77.20 K(+15.4%)
Mar 2014
-
-$16.80 K(-114.5%)
$66.90 K(+0.6%)
Dec 2013
$68.90 K(-173.0%)
-
-
Dec 2013
-
$115.90 K(-668.1%)
$66.50 K(-167.5%)
Sep 2013
-
-$20.40 K(+72.9%)
-$98.50 K(+2.4%)
Jun 2013
-
-$11.80 K(-31.4%)
-$96.20 K(+6.3%)
Mar 2013
-
-$17.20 K(-65.0%)
-$90.50 K(-4.5%)
Dec 2012
-$94.40 K(-65.8%)
-
-
Dec 2012
-
-$49.10 K(+171.3%)
-$94.80 K(-39.3%)
Sep 2012
-
-$18.10 K(+196.7%)
-$156.10 K(-22.7%)
Jun 2012
-
-$6100.00(-71.6%)
-$201.90 K(-21.8%)
Mar 2012
-
-$21.50 K(-80.5%)
-$258.30 K(+9.1%)
Dec 2011
-$276.30 K(-94.6%)
-
-
Dec 2011
-
-$110.40 K(+72.8%)
-$236.80 K(-95.4%)
Sep 2011
-
-$63.90 K(+2.2%)
-$5.19 M(+0.3%)
Jun 2011
-
-$62.50 K(<-9900.0%)
-$5.17 M(+1.2%)
Mar 2011
-
$0.00(-100.0%)
-$5.11 M(-1.1%)
Dec 2010
-$5.13 M(+329.6%)
-
-
Dec 2010
-
-$5.06 M(>+9900.0%)
-$5.17 M(+318.0%)
Sep 2010
-
-$48.10 K(<-9900.0%)
-$1.24 M(-0.0%)
Jun 2010
-
$0.00(-100.0%)
-$1.24 M(-3.0%)
Mar 2010
-
-$59.20 K
-$1.28 M
DateAnnualQuarterlyTTM
Dec 2009
-$1.19 M(+169.7%)
-
-
Dec 2009
-
-$1.13 M(+2232.6%)
-$1.27 M(+158.3%)
Sep 2009
-
-$48.40 K(+24.7%)
-$490.80 K(+31.4%)
Jun 2009
-
-$38.80 K(-24.8%)
-$373.50 K(-7.7%)
Mar 2009
-
-$51.60 K(-85.3%)
-$404.70 K(-2.3%)
Dec 2008
-$442.50 K(-22.7%)
-
-
Dec 2008
-
-$352.00 K(-610.9%)
-$414.20 K(-24.5%)
Sep 2008
-
$68.90 K(-198.4%)
-$548.60 K(-14.1%)
Jun 2008
-
-$70.00 K(+14.6%)
-$639.00 K(+2.4%)
Mar 2008
-
-$61.10 K(-87.4%)
-$624.20 K(+2.2%)
Dec 2007
-$572.10 K(+182.1%)
-
-
Dec 2007
-
-$486.40 K(+2162.3%)
-$611.00 K(+1871.0%)
Sep 2007
-
-$21.50 K(-61.1%)
-$31.00 K(-29.4%)
Jun 2007
-
-$55.20 K(+15.2%)
-$43.90 K(-77.9%)
Mar 2007
-
-$47.90 K(-151.2%)
-$198.80 K(-0.9%)
Dec 2006
-$202.80 K(+21.2%)
-
-
Dec 2006
-
$93.60 K(-372.1%)
-$200.70 K(-42.9%)
Sep 2006
-
-$34.40 K(-83.6%)
-$351.20 K(+5.8%)
Jun 2006
-
-$210.10 K(+321.9%)
-$332.00 K(+110.1%)
Mar 2006
-
-$49.80 K(-12.5%)
-$158.00 K(-42.2%)
Dec 2005
-$167.30 K(+10.1%)
-
-
Dec 2005
-
-$56.90 K(+274.3%)
-$273.50 K(-30.2%)
Sep 2005
-
-$15.20 K(-57.9%)
-$392.10 K(+6.2%)
Jun 2005
-
-$36.10 K(-78.2%)
-$369.20 K(+2.0%)
Mar 2005
-
-$165.30 K(-5.8%)
-$362.00 K(+51.2%)
Dec 2004
-$151.90 K(-30.8%)
-
-
Dec 2004
-
-$175.50 K(-2379.2%)
-$239.40 K(+14.1%)
Sep 2004
-
$7700.00(-126.6%)
-$209.80 K(-11.8%)
Jun 2004
-
-$28.90 K(-32.3%)
-$237.90 K(-2.3%)
Mar 2004
-
-$42.70 K(-70.7%)
-$243.50 K(+7.6%)
Dec 2003
-$219.50 K(+120.6%)
-
-
Dec 2003
-
-$145.90 K(+615.2%)
-$226.30 K(+123.4%)
Sep 2003
-
-$20.40 K(-40.9%)
-$101.30 K(+0.1%)
Jun 2003
-
-$34.50 K(+35.3%)
-$101.20 K(+0.6%)
Mar 2003
-
-$25.50 K(+22.0%)
-$100.60 K(+0.9%)
Dec 2002
-$99.50 K(-19.5%)
-
-
Dec 2002
-
-$20.90 K(+3.0%)
-$99.70 K(+29.6%)
Sep 2002
-
-$20.30 K(-40.1%)
-$76.90 K(-30.5%)
Jun 2002
-
-$33.90 K(+37.8%)
-$110.60 K(-25.6%)
Mar 2002
-
-$24.60 K(-1394.7%)
-$148.60 K(-0.8%)
Dec 2001
-$123.60 K(+24.2%)
-
-
Dec 2001
-
$1900.00(-103.5%)
-$149.80 K(-16.4%)
Sep 2001
-
-$54.00 K(-24.9%)
-$179.10 K(+21.4%)
Jun 2001
-
-$71.90 K(+178.7%)
-$147.50 K(+45.9%)
Mar 2001
-
-$25.80 K(-5.8%)
-$101.10 K(+1.8%)
Dec 2000
-$99.50 K(-15.0%)
-
-
Dec 2000
-
-$27.40 K(+22.3%)
-$99.30 K(+8.3%)
Sep 2000
-
-$22.40 K(-12.2%)
-$91.70 K(-3.6%)
Jun 2000
-
-$25.50 K(+6.3%)
-$95.10 K(-10.1%)
Mar 2000
-
-$24.00 K(+21.2%)
-$105.80 K(-9.6%)
Dec 1999
-$117.10 K(-2.2%)
-
-
Dec 1999
-
-$19.80 K(-23.3%)
-$117.00 K(+7.1%)
Sep 1999
-
-$25.80 K(-28.7%)
-$109.20 K(-5.1%)
Jun 1999
-
-$36.20 K(+2.8%)
-$115.10 K(-5.5%)
Mar 1999
-
-$35.20 K(+193.3%)
-$121.80 K(+0.9%)
Dec 1998
-$119.70 K(-40.1%)
-
-
Dec 1998
-
-$12.00 K(-62.1%)
-$120.70 K(-24.2%)
Sep 1998
-
-$31.70 K(-26.1%)
-$159.30 K(-3.0%)
Jun 1998
-
-$42.90 K(+25.8%)
-$164.20 K(-18.1%)
Mar 1998
-
-$34.10 K(-32.6%)
-$200.40 K(+0.6%)
Dec 1997
-$199.70 K(+24.7%)
-
-
Dec 1997
-
-$50.60 K(+38.3%)
-$199.30 K(+34.0%)
Sep 1997
-
-$36.60 K(-53.7%)
-$148.70 K(+32.6%)
Jun 1997
-
-$79.10 K(+139.7%)
-$112.10 K(+239.7%)
Mar 1997
-
-$33.00 K
-$33.00 K
Dec 1996
-$160.20 K
-
-

FAQ

  • What is ImmunoPrecise Antibodies annual EBITDA?
  • What is the all time high annual EBITDA for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies annual EBITDA year-on-year change?
  • What is ImmunoPrecise Antibodies quarterly EBITDA?
  • What is the all time high quarterly EBITDA for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies quarterly EBITDA year-on-year change?
  • What is ImmunoPrecise Antibodies TTM EBITDA?
  • What is the all time high TTM EBITDA for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies TTM EBITDA year-on-year change?

What is ImmunoPrecise Antibodies annual EBITDA?

The current annual EBITDA of IPA is -$16.99 M

What is the all time high annual EBITDA for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high annual EBITDA is $68.90 K

What is ImmunoPrecise Antibodies annual EBITDA year-on-year change?

Over the past year, IPA annual EBITDA has changed by -$1.17 M (-7.42%)

What is ImmunoPrecise Antibodies quarterly EBITDA?

The current quarterly EBITDA of IPA is -$1.12 M

What is the all time high quarterly EBITDA for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high quarterly EBITDA is $611.70 K

What is ImmunoPrecise Antibodies quarterly EBITDA year-on-year change?

Over the past year, IPA quarterly EBITDA has changed by +$1.35 M (+54.74%)

What is ImmunoPrecise Antibodies TTM EBITDA?

The current TTM EBITDA of IPA is -$17.87 M

What is the all time high TTM EBITDA for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high TTM EBITDA is $1.70 M

What is ImmunoPrecise Antibodies TTM EBITDA year-on-year change?

Over the past year, IPA TTM EBITDA has changed by -$208.40 K (-1.18%)